期刊文献+

凝血酶原基因G20210A突变检测对肺血栓栓塞症的预测价值 被引量:3

Predictive value of prothrombin G20210 Amutation detection in pulmonary thromboembolism
下载PDF
导出
摘要 目的:探讨凝血酶原基因G20210A(FⅡG20210A)突变在中国东北地区肺血栓栓塞症(PTE)患者中的发生频率,阐明检测该突变基因对中国东北地区人群PTE的预测价值。方法:选择经核素肺灌注显像和(或)螺旋CT肺动脉造影(CTPA)结合临床症状确诊的PTE患者60例(病例组)和同期来自相同地区、性别和年龄相匹配的正常健康人80名(对照组)。应用蛋白酶消化及乙醇抽提获得2组研究对象的DNA。采用聚合酶链式反应(PCR)、HindⅢ限制性内切酶片段多态性分析(RFLP)和琼脂糖凝胶电泳检测病例组和对照组研究对象FⅡG20210A基因突变情况。结果:经HindⅢ酶切后,病例组仅出现407和99bp 2个条带,FⅡG20210A突变频率为0%,与对照组比较差异无统计学意义(P>0.05);病例组和对照组均未发现FⅡG20210A基因杂合子或纯合子突变。结论:FⅡG20210A基因突变在我国东北地区PTE患者中发生率低,FⅡG20210A基因突变检测可能对中国东北地区人群PTE无预测价值。 Objective To study the incidence frequency of prothrombin G20210A (FⅡ G20210A)mutation in the patients with pulmonary thromboembolism(PTE)in northeast China,and to clarify the predictive value of FⅡG20210A mutation detection in PTE of the population in northeast China.Methods 60 PTE patients(PTE group) and 80 sex-matched healthy controls(control group)from the same geographic area were selected.All the patients were diagnosed by lung ventilation/perfusion scan and/or multi-slice CT pulmonary angiography(CTPA)as well as medical history.The genome DNA was extracted from the whole blood using alcohol.Polymerase chain reaction (PCR),restriction fragment length polymorphisms(RFLP)analysis with HindⅢ restriction enzyme and sepharose gel electrophoresis were used to identify the F Ⅱ G20210A mutation in PTE group and control group. Results After digested by HindⅢ restriction enzyme,only the fragments of 407 and 99 bp were found in PTE group.The frequency of FⅡ G20210A mutation was 0%,there was no statistical difference compared with contol group(P>0.05).There were no heterozygote and homozygote mutation of FⅡ G202210A gene in PTE group and control group.Conclusion The incidence of FⅡ G20210A mutation in the PTE patients in northeast China is very low,and the detection of FⅡ G20210A mutation may have no predictive value in PTE of the population in northeast China.
出处 《吉林大学学报(医学版)》 CAS CSCD 北大核心 2014年第5期1080-1084,共5页 Journal of Jilin University:Medicine Edition
基金 吉林省科技厅科研基金资助课题(201115092)
关键词 肺血栓栓塞症 G20210A基因 凝血酶原 pulmonary thromboembolism G20210A gene prothrombin
  • 相关文献

参考文献21

  • 1Tutan O,ündar B,Günay T,et al.Investigation of inherited thrombophilias in patients with pulmonary embolism[J].Blood Coagulat Fibrin,2013,24(2):140-149.
  • 2王辰,翟振国.中危肺血栓栓塞症的诊断依据与临床意义[J].中国实用内科杂志,2013,33(2):93-97. 被引量:9
  • 3刘璠,朱然,康健.癌症相关急性肺血栓栓塞症序贯抗凝治疗的研究[J].中国实用内科杂志,2014,34(2):183-186. 被引量:8
  • 4Tang YY,Sampson B,Pack S,et al.Ethnic differences in Out-of-Hospital fatal pulmonary embolism[J].Circulation,2011,123(20):2219-2225.
  • 5Kupeli E,Verdi H,Simsek A,et al.Genetic mutations in Turkish population with pulmonary embolism and deep venous thrombosis[J].Thromb Hemost,2011,17(6):87-94.
  • 6Gohil R,Peck G,Sharma P,et al.The genetics of venous thromboembolism.A meta-analysis involving approximately120 000cases and 180 000controls[J].Thromb Haemost,2009,102(2):360-370.
  • 7Ro A,Hara M,Takada A,et al.The facorⅤLeiden mutation and the prothrombin G20210A mutation was not found in Japanese patients with pulmonary thromboembolism[J].Thromb Haemost,1999,82(6):1769-1769.
  • 8Obeidat NM,Awidi A,Sulaiman NA,et al.Thrombophilia-related genetic variations in patients with pulmonary embolism in the main teaching hospital in Jordan[J].Saudi Med J,2009,30(7):921-925.
  • 9肺血栓栓塞症的诊断与治疗指南(草案)[J].中华结核和呼吸杂志,2001,24(5):259-264. 被引量:1839
  • 10Huber S,McMaster KJ,Voelkerding KV,et al.Analytical evaluation of primer engineered multiplex polymerase chain reaction-restriction fragment length polymorphism for detection of factorⅤLeiden and Prothrombin G20210A[J].J Mol Diagn,2000,2(3):153-157.

二级参考文献34

  • 1郭丹杰.肺动脉血栓栓塞的诊治策略[J].郑州大学学报(医学版),2009,44(6):1123-1126. 被引量:1
  • 2储海燕,诸江,王鸿利,邵慧珍,张庆华,张宇舟,王学锋,杨景文,陈竺,王振义.上海地区深静脉血栓形成患者抗活化的蛋白C及FⅤLeiden突变的初步调查[J].中华血液学杂志,1996,17(9):462-465. 被引量:34
  • 3Sambrook JM 金冬雁等(译).分子克隆实验指南(第2版)[M].北京:科学出版社,1993.464.
  • 4De Stefano V,Martinelli I,Leone G,et al.The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor Ⅴ Leiden and the G20210A prothrombin mutation.N Eng J Med,1999,341(11):801.
  • 5Gerhardt A,Scharf RE,Beckmann MW,et al.Prothrombin and factor Ⅴ mutations in women with a history of thrombosis during pregnancy and the puerperium.N Eng J Med,2000,342(6):374.
  • 6Rosendaal FR,Doggen CJM,Zivelin A,et al.Geographic distribution of the 20210 G to a prothrombin variant.Thromb Haemost,1998,79 (4):706.
  • 7Mansourati J,Da Costa A,Munier S,et al.Prevalence of factor Ⅴ Leiden in patients with myocardial infarction and normal coronary angiography.Thromb Haemost,2000,83(6):822.
  • 8Linfert DR,Rezuke WN,Tsongalis GJ.Rapid multiplex analysis for the Factor V Leiden and prothrombin G20210Amutations associated with hereditary thrombophilia.Conn Med,1998,62(9):519.
  • 9Dahlback B,Hildebrand B.Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor Ⅴ.Proc.Natl.Acad Sci USA,1994,91(4):1396.
  • 10Gregg JP,Yamane A J,Grody WW.Prevalence of the factor Ⅴ-Leiden mutation in four distinct American ethnic populations.Am J Med Genet,1997,73(3):334.

共引文献1878

同被引文献29

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部